Recon: FDA authorizes updated COVID vaccines; NICE finds Alzheimer’s drug Leqembi too pricey for NHS use

ReconReconApproval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalHealth technology assessment (HTA)Medical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReimbursementUnited States